Simultaneous irradiation for prostate cancer: Intermediate results with modern techniques

Journal of Urology

Volumn 164, Issue 3 I, 2000, Pages 738-743

  Critz, Frank A ^a   Williams, W Hamilton ^a   Levinson, A Keith ^a   Benton, James B ^a   Holladay, Clinton T ^a   Schnell Jr , Frederick J ^a  

^a Radiother Clinics Georgia G   (United States)

Author keywords

Brachytherapy; Prostate; Prostatic neoplasms; Radioisotopes; Radiotherapy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER STAGING; CANCER SURVIVAL; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; TREATMENT OUTCOME;

EID: 0033870344     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0022-5347(05)67293-x     Document Type: Article

References (15)

1. Whitmore, W. F, Jr., Hilaris, B. and Grabstald, H.: Retropubic implantation of iodine 125 in the treatment of prostatic cancer. J Urol, 108: 918, 1972
2. 125iodine implantation of the prostate for clinically localized prostatic cancer. J Urol, 158: 23, 1997
3. Critz, F. A., Williams, W. H., Holladay, C. T. et al: Posttreatment PSA ≤ 0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques. Urology, 54: 968, 1999
4. Beyer, D. C. and Priestley, J. B., Jr.: Biochemical disease-free survival following 1251 prostate implantation. Int J Radiat Oncol Biol Phys, 37: 559, 1997
5. Fukunaga-Johnson, N., Sandler, H. M., McLaughlin, P. W. et al: Results of 3D conformal radiotherapy in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys, 38: 311, 1997
6. Hanks, G. E., Lee, W. R. and Schultheiss, T. E.: Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J Urol, 154: 456, 1995
7. Wallner, K., Roy, J. and Harrison, L.: Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol, 14: 449, 1996
8. Consensus statement: guidelines for PSA following radiation therapy. American Society for Therapeutic Radiology and Oncology Consensus Panel. Int J Radiat Oncol Biol Phys, 37: 1035, 1997
9. Vicini, F. A., Horwitz, E. M., Gonelez, J. et al: Treatment options for localized prostate cancer based on pretreatment serum prostate specific antigen levels. J Urol, 158: 319, 1997
10. Critz, F. A., Levinson, A. K., Williams, W. H. et al: Prostatespecific antigen nadir.: the optimum level after irradiation for prostate cancer. J Clin Oncol, 14: 2893, 1996
11. 125I implantation for stage T1/T2 prostatic carcinoma. J Urol, 154: 1096, 1995
12. Schellhammer, P. F., El-Mahdi, A. M., Wright, G. L. et al: Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of the prostate. Urology, 42: 13, 1993
13. Ragde, H., Elgamal A. A., Snow, P. B. et al: Ten-year disease free survival after transperineal sonography-guided iodine-125 brachytherapy with or without 45-gray external beam irradiation in the treatment of patients with clinically localized, low to high Gleason grade prostate carcinoma. Cancer, 83: 989, 1998
14. Pound, C. R., Partin, A. W., Epstein, J. I. et al: Prostate-specific antigen after anatomic radical retropubic prostatectomy. Urol Clin North Am, 24: 395, 1997
15. Catalona, W. J. and Smith, D. S.: Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol, part 2, 160: 2428, 1998